Statement of Principles
concerning
MALIGNANT NEOPLASM OF THE LUNG
No. 18 of 2006
for the purposes of the
Veterans’ Entitlements Act 1986
and
Military Rehabilitation and
Compensation Act 2004
Title
1.
This Instrument may be cited
as Statement of Principles concerning malignant neoplasm of the lung No. 18 of
2006.
Determination
2.
The Repatriation Medical
Authority under subsection 196B(3) and (8) of the Veterans’
Entitlements Act 1986 (the VEA):
(a) revokes Instrument No. 36 of 2001; and
(b) determines in their place this Statement of Principles.
Kind of injury, disease
or death
3. (a) This Statement of Principles is
about malignant neoplasm of the lung and death from malignant
neoplasm of the lung.
(b)
For the purposes of this Statement
of Principles, “malignant neoplasm of the lung” means a primary
malignant neoplasm arising from the cells of the trachea, bronchus, or lung.
This definition excludes soft tissue sarcoma, non-Hodgkin’s lymphoma, Hodgkin’s
lymphoma, carcinoid tumour and malignant neoplasm of the pleura.
(c)
Malignant neoplasm of the lung
attracts ICD-10-AM codes C33, C34.
(d)
In the application of this
Statement of Principles, the definition of “malignant neoplasm of the lung” is
that given at paragraph 3(b) above.
Basis for determining the
factors
4. On the sound medical-scientific evidence available, the
Repatriation Medical Authority is of the view that it is more probable than not
that malignant neoplasm of the lung and death from malignant neoplasm
of the lung can be related to relevant service rendered by veterans or
members of the Forces under the VEA, or members under the Military
Rehabilitation and Compensation Act 2004 (the MRCA).
Factors that must be
related to service
5. Subject to clause 7, at least one of the factors set out in
clause 6 must be related to the relevant service rendered by the person.
Factors
6. The factor that must exist before it can be said that, on the
balance of probabilities, malignant neoplasm of the lung or death
from malignant neoplasm of the lung is connected with the circumstances of
a person’s relevant service is:
(a)
for each of the following types of
malignant neoplasm of the lung:
(i) squamous cell carcinoma;
(ii) small cell carcinoma;
(iii) malignant neoplasm of undetermined
histology;
(iv) large cell carcinoma; or
(v) carcinosarcoma
smoking at least one half of a pack year of cigarettes
or the equivalent thereof in other tobacco products, before the clinical onset
of malignant neoplasm of the lung, where smoking commenced at least ten years
before the clinical onset of malignant neoplasm of the lung; or
(b)
for adenocarcinoma of the lung
only, smoking at least three pack years of cigarettes or the equivalent thereof
in other tobacco products, before the clinical onset of malignant neoplasm of
the lung, where smoking commenced at least ten years before the clinical onset
of malignant neoplasm of the lung; or
(c)
being in an atmosphere
with a visible tobacco smoke haze in an enclosed space for at least 5000 hours before the clinical onset of malignant neoplasm of the lung,
where the first exposure to a visible tobacco smoke haze commenced at least ten
years before the clinical onset of malignant neoplasm of the lung; or
(d)
inhaling respirable asbestos
fibres in an enclosed space at the time material containing asbestos fibres was
being applied, removed, dislodged, cut or drilled, at least ten years before
the clinical onset of malignant
neoplasm of the lung; or
(e)
inhaling respirable asbestos
fibres in an open environment for a cumulative period of at least 1000 hours
before the clinical onset of malignant
neoplasm of the lung:
(i)
at the time material containing
asbestos fibres was being applied, removed, dislodged, cut or drilled; and
(ii)
the first inhalation of asbestos
occurred at least ten years
before
the clinical onset of malignant
neoplasm of the lung; or
(f)
having asbestosis at the time of
the clinical onset of malignant neoplasm of the lung; or
(g)
being within 100 metres of an
industrial coke oven for a cumulative period of at least 4500 hours, at least
ten years before the clinical onset of malignant neoplasm of the lung; or
(h)
being heavily exposed to diesel
engine exhaust for a cumulative period of at least 15 000 hours, at least ten
years before the clinical onset of malignant neoplasm of the lung; or
(i)
inhaling, ingesting or
having cutaneous contact with a chemical agent contaminated by
2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) for a cumulative period of at
least thirty days, at least ten years before the clinical onset of malignant neoplasm of the
lung; or
(j)
inhaling mustard gas at least ten
years before the clinical onset of malignant neoplasm of the lung; or
(k)
having received a cumulative
equivalent dose of 0.5 Sievert of atomic radiation to the lung, where this dose
was accumulated at least ten years before the clinical onset of malignant
neoplasm of the lung; or
(l)
having received a course of
therapeutic radiation to the thorax before the clinical onset of malignant
neoplasm of the lung, where the first exposure occurred at least ten years
before the clinical onset of malignant neoplasm of the lung; or
(m)
being exposed to at least 120
Working Level Months (WLM) of radon in an enclosed space, before the clinical
onset of malignant neoplasm of the lung, where the first exposure to radon
occurred at least ten years before the clinical onset of malignant neoplasm of
the lung; or
(n)
having silicosis at the time of
the clinical onset of malignant neoplasm of the lung; or
(o)
inhaling fumes of a substance from
the specified list:
(i)
for at least four hours per day on
more days than not for at least five years or for a cumulative period of at
least 3500 hours, before the clinical onset of malignant neoplasm of the lung;
and
(ii)
the first inhalation of fumes
occurred at least ten years before the clinical onset of malignant neoplasm of
the lung; or
(p)
having berylliosis at the time of
the clinical onset of malignant neoplasm of the lung; or
(q)
inability to obtain appropriate
clinical management for malignant neoplasm of the lung.
Factors that apply only
to material contribution or aggravation
7. Paragraph 6(q) applies only to material contribution
to, or aggravation of, malignant neoplasm of the lung where the person’s
malignant neoplasm of the lung was suffered or contracted before or during (but
not arising out of) the person’s relevant service.
Inclusion
of Statements of Principles
8.
In this Statement of
Principles if a relevant factor applies and that factor includes an injury or
disease in respect of which there is a Statement of Principles then the factors
in that last mentioned Statement of Principles apply in accordance with the
terms of that Statement of Principles as in force from time to time.
Other definitions
9.
For the purposes of this
Statement of Principles:
“a course of therapeutic radiation” means one or more fractions
(treatment portions) of ionising radiation administered with the aim of
achieving palliation or cure with gamma rays, x-rays, alpha particles or beta
particles;
“a substance from the specified list” means:
(i)
beryllium;
(ii)
bis(chloromethyl)ether;
(iii)
cadmium;
(iv)
chloromethyl methyl ether;
(v)
cobalt metal with tungsten
carbide;
(vi)
hexavalent chromate;
(vii)
inorganic arsenic; or
(viii)
nickel;
“an enclosed space” means a
substantially enclosed area, for example the interior of a building, ship or
aircraft, a covered workshop or factory;
“atomic radiation” means ionising radiation excluding;
(i)
natural background radiation;
(ii)
therapeutic radiation; and
(iii)
radiation from diagnostic
procedures;
“being heavily exposed to diesel engine exhaust” means:
(i)
being an occupant in an enclosed
diesel powered vehicle cabin contaminated with diesel fumes; or
(ii)
working in an enclosed space where
diesel powered engines or motors are being operated; or
(iii)
repairing and/or servicing diesel
engines;
“berylliosis”
(synonymous with chronic beryllium disease) means a granulomatous disease
usually involving the lungs, but which may involve the skin or other
structures, and is induced by a delayed hypersensitivity reaction to beryllium
fumes;
“cumulative equivalent dose” means the total equivalent dose of radiation from all
types of ionising radiation. It accounts for the differences in biological
effectiveness of various types of radiation and allows doses from different
radiations to be combined. Each component is calculated by multiplying the
absorbed dose in a particular tissue or organ for a given type of radiation by
the radiation weighting factor for that radiation. The unit of equivalent dose
is the Sievert (Sv);
“death from malignant neoplasm of the lung” in relation to a person includes death from a terminal
event or condition that was contributed to by the person’s malignant neoplasm
of the lung;
“fumes” means
combustion products, aerosols, vapours or dust arising through industrial
processes or from workplace practices that involve the refining, manufacture or
use of the stated material;
“ICD-10-AM code” means a number assigned to a particular kind of injury or disease in
The International Statistical Classification of Diseases and Related Health
Problems, 10th revision, Australian Modification (ICD-10-AM), Fourth Edition,
effective date of 1 July 2004, copyrighted by the National Centre for
Classification in Health, Sydney, NSW, and having ISBN 1 86487 594 1;
“inhaling, ingesting or having cutaneous contact with
a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD)” means:
(a)
decanting or spraying;
(b)
cleaning or maintaining equipment
used to apply;
(c)
being sprayed with;
(d)
handling or sawing timber treated
with;
(e)
being in an environment shrouded
in dust from timber treated with; or
(f)
using cutting oils contaminated
with;
one of the following chemicals:
·
2,4,5-trichlorophenoxyacetic acid;
·
2,4,5-trichlorophenoxypropionic
acid;
·
2,4,5-trichlorophenol;
·
2-(2,4,5-trichlorophenoxy)-ethyl
2,2-dichloropropionate;
·
o,o-dimethyl-o-(2,4,5-trichlorophenyl)-phosphorothioate;
·
pentachlorophenol;
·
2,3,4,6-tetrachlorophenol;
·
2,4,6-trichlorophenol;
·
1,3,4-trichloro-2-(4-nitrophenoxy)benzene;
·
2,4-dichloro-1-(4-nitrophenoxy)benzene;
or
·
2,4-dichloro-1-(3-methoxy-4-nitrophenoxy)-benzene;
“pack years of cigarettes, or the equivalent thereof
in other tobacco products” means a
calculation of consumption where one pack year of cigarettes equals twenty tailor
made cigarettes per day for a period of one calendar year, or 7300 cigarettes.
One tailor made cigarette approximates one gram of tobacco or one gram of cigar
or pipe tobacco by weight. One pack year of tailor made cigarettes equates to 7
300 cigarettes, or 7.3kg of smoking tobacco by weight. Tobacco products means
either cigarettes, pipe tobacco or cigars smoked, alone or in any combination;
“relevant service” means:
(a) eligible war service (other than
operational service) under the VEA; or
(b) defence service (other than
hazardous service) under the VEA; or
(c)
peacetime service under the MRCA;
“respirable asbestos fibres” means asbestos fibres less than five micrometres in
diameter;
“terminal event” means the proximate or ultimate cause of death and includes:
(a) pneumonia;
(b) respiratory failure;
(c) cardiac arrest;
(d) circulatory failure; or
(e)
cessation of brain function;
“Working Level (WL)” is any combination of radon progeny in 1 litre of air that ultimately
releases 1.3 C 105 million electron volts (MeV) of alpha
energy during decay;
“Working Level Month (WLM)” is exposure to 1 Working Level (WL) for 170 hours.
Application
10. This Instrument applies to all matters to which
section 120B of the VEA or section 339 of the MRCA applies.
Date of effect
11. This Instrument takes effect from 10 May 2006.
Notes to Statement of Principles concerning malignant
neoplasm of the lung (Instrument No. 18 of 2006)
The Statement of Principles concerning malignant neoplasm of
the lung (Instrument No. 18 of 2006) in force under section 196B(3) of the Veterans’
Entitlements Act 1986, as shown in this compilation is amended as indicated
in the Tables below.
Table
of Instruments
|
Title
|
Date of notification
in Gazette or FRLI registration
|
Date of
commencement
|
Application, saving or
transitional provisions
|
|
Statement
of Principles concerning malignant neoplasm of the lung (Instrument No. 18 of
2006)
|
3 May 2006
|
10 May 2006
|
|
|
Amendment
Statement of Principles concerning malignant neoplasm of the lung (Instrument
No. 88 of 2007)
|
27 June 2007
|
4 July 2007
|
|
Table of Amendments
|
ad. = added or inserted am. = amended
rep. = repealed rs. = repealed and substituted
|
|
Provision affected
|
How affected
|
|
Clause 9 – ‘a substance from the specified list’.....
|
rs. Instrument No.87 of 2007
|
|
|
|